Ισραήλ - Εβραϊκά - Ministry of Health

eli lilly israel ltd, israel - olanzapine - טבליה - olanzapine 5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Ισραήλ - Εβραϊκά - Ministry of Health

eli lilly israel ltd, israel - olanzapine - טבליה - olanzapine 7.5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Ισραήλ - Εβραϊκά - Ministry of Health

eli lilly israel ltd, israel - olanzapine - טבליה - olanzapine 7.5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Ισραήλ - Εβραϊκά - Ministry of Health

eli lilly israel ltd, israel - olanzapine - טבליות מסיסות בפה - olanzapine 5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Ισραήλ - Εβραϊκά - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

Ισραήλ - Εβραϊκά - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

Ισραήλ - Εβραϊκά - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

Ισραήλ - Εβραϊκά - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Ισραήλ - Εβραϊκά - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Ισραήλ - Εβραϊκά - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.